{"id":204489,"date":"2026-04-21T11:49:00","date_gmt":"2026-04-21T15:49:00","guid":{"rendered":"https:\/\/testing.news-you-need.com\/index.php\/2026\/04\/21\/insilico-medicine-announces-industrys-first-longevity-board-to-accelerate-ai-driven-aging-research-for-drug-discovery\/"},"modified":"2026-04-21T12:00:14","modified_gmt":"2026-04-21T16:00:14","slug":"insilico-medicine-announces-industrys-first-longevity-board-to-accelerate-ai-driven-aging-research-for-drug-discovery","status":"publish","type":"post","link":"https:\/\/testing.news-you-need.com\/index.php\/2026\/04\/21\/insilico-medicine-announces-industrys-first-longevity-board-to-accelerate-ai-driven-aging-research-for-drug-discovery\/","title":{"rendered":"Insilico Medicine announces industry\u2019s first longevity board to accelerate AI-driven aging research for drug discovery"},"content":{"rendered":"<p><a href=\"https:\/\/www.eurekalert.org\/news-releases\/1125084\">Insilico Medicine announces industry\u2019s first longevity board to accelerate AI-driven aging research for drug discovery<\/a><\/p>\n<p><a href=\"https:\/\/www.eurekalert.org\/news-releases\/1125084\">https:\/\/www.eurekalert.org\/news-releases\/1125084<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-04-21 11:49:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.eurekalert.org\">www.eurekalert.org<\/a><\/p>\n<ul>\n<li>\n<p><strong>Formation of Insilico Medicine&#8217;s Longevity Board<\/strong>: Insilico Medicine has established the industry\u2019s first Longevity Board, aiming to provide scientific oversight and strategic guidance for AI-enabled aging research and drug discovery initiatives. <\/p>\n<\/li>\n<li>\n<p><strong>Key Board Members<\/strong>: The Board includes prominent figures such as Andrew Adams, Chairman and Group Vice President of Molecular Discovery at Eli Lilly, Nobel Laureate Michael Levitt, and other experts like Alex and Feng Zhavoronkov of Insilico Medicine.<\/p>\n<\/li>\n<li>\n<p><strong>Objectives of the Board<\/strong>: The initiative is intended to accelerate the development of therapeutics targeting the fundamental biological processes of aging, and enhance the transition from reactive disease care to proactive healthspan and peakspan extension.<\/p>\n<\/li>\n<li>\n<p><strong>Integration of AI and Traditional Pharmaceutical Methods<\/strong>: The Board will focus on using biomarkers and foundation models, integrating advanced AI technologies with traditional large-scale pharmaceutical development to create commercially viable longevity drugs.<\/p>\n<\/li>\n<li>\n<p><strong>Historical Context and Future Scope<\/strong>: Longevity science has been an important aspect of Insilico Medicine since its inception, employing AI to identify dual-purpose targets for diseases closely linked to aging, thus broadening the scope beyond mere disease therapy to modulating aging itself.<\/p>\n<\/li>\n<li>\n<p><strong>AI Technology Driving Innovation<\/strong>: Insilico leverages generative AI to explore new therapeutic targets which can address immediate clinical needs and the underlying biological processes of aging.<\/p>\n<\/li>\n<li>\n<p><strong>Established Leadership and Commitment<\/strong>: Michael Levitt and other board members highlight the importance and ambition of this endeavor, reflecting over a decade of scientific and technological advancements in the field of longevity.<\/p>\n<\/li>\n<li>\n<p><strong>Broader Applications of AI in Biotechnology<\/strong>: Insilico Medicine isn\u2019t just focused on aging; it incorporates AI to address various unmet medical needs in fields like fibrosis, oncology, and metabolic disorders, extending its Pharma.AI technologies to numerous industries.<\/p>\n<\/li>\n<\/ul>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine announces industry\u2019s first longevity board to accelerate AI-driven aging research for drug discovery&#8230;<\/p>\n","protected":false},"author":1,"featured_media":204490,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/mediasvc.eurekalert.org\/Api\/v1\/Multimedia\/31678607-3906-4a26-bd91-c0f7f0118d4d\/Rendition\/thumbnail\/Content\/Public","fifu_image_alt":"","footnotes":""},"categories":[14],"tags":[19],"class_list":["post-204489","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-artificial-intelligence","tag-generative-ai"],"_links":{"self":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/204489"}],"collection":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=204489"}],"version-history":[{"count":1,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/204489\/revisions"}],"predecessor-version":[{"id":204491,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/204489\/revisions\/204491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/204490"}],"wp:attachment":[{"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=204489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=204489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/testing.news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=204489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}